Journal Article

DKFZ-2023-01803

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma.

Heim, C. ; Moser, L. M.DKFZ* ; Kreyenberg, H. ; Bonig, H. B. ; Tonn, T.DKFZ* ; Wels, W. S.DKFZ* ; Gradhand, E. ; Ullrich, E.DKFZ* ; Meister, M. T. ; Koerkamp, M. G. ; Holstege, F. C. P. ; Drost, J. ; Klusmann, J.-H.DKFZ* ; Bader, P. ; Merker, M. ; Rettinger, E.DKFZ*

2023
Frontiers Media Lausanne

This record in other databases:  

Please use a persistent id in citations: doi:10.3389/fimmu.2023.1228894

Abstract: Metastatic rhabdomyosarcoma (RMS) is a challenging tumor entity that evades conventional treatments and endogenous antitumor immune responses, highlighting the need for novel therapeutic strategies. Applying chimeric antigen receptor (CAR) technology to natural killer (NK) cells may offer safe, effective, and affordable therapies that enhance cancer immune surveillance.Here, we assess the efficacy of clinically usable CAR-engineered NK cell line NK-92/5.28.z against ErbB2-positive RMS in vitro and in a metastatic xenograft mouse model.Our results show that NK-92/5.28.z cells effectively kill RMS cells in vitro and significantly prolong survival and inhibit tumor progression in mice. The persistence of NK-92/5.28.z cells at tumor sites demonstrates efficient antitumor response, which could help overcome current obstacles in the treatment of solid tumors.These findings encourage further development of NK-92/5.28.z cells as off-the-shelf immunotherapy for the treatment of metastatic RMS.

Keyword(s): Humans (MeSH) ; Animals (MeSH) ; Mice (MeSH) ; Rhabdomyosarcoma, Alveolar: therapy (MeSH) ; Receptors, Chimeric Antigen: genetics (MeSH) ; Immunotherapy (MeSH) ; Rhabdomyosarcoma: therapy (MeSH) ; Disease Models, Animal (MeSH) ; Killer Cells, Natural (MeSH) ; Neoplasms, Second Primary (MeSH) ; ERBB2 (HER2/neu) ; cancer immunotherapy ; chimeric antigen receptor ; rhabdomyosarcoma ; xenograft ; Receptors, Chimeric Antigen

---

Contributing Institute(s):

1. DKTK Koordinierungsstelle Frankfurt (FM01)
2. DKTK Koordinierungsstelle Dresden (DD01)

Research Program(s):

1. 899 - ohne Topic (POF4-899) (POF4-899)

Appears in the scientific report 2023

---

Database coverage:
; ; ; Article Processing Charges ; Clarivate Analytics Master Journal List ; DOAJ Seal ; Essential Science Indicators ; Fees ; IF >= 5 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---